Keyword: cost management

193 results found
What dental benefits topics should plan sponsors be considering?

With prescription drugs and paramedical benefits taking up an increasingly large portion of employers’ benefits spend, dental benefits often avoid the spotlight. But consultants and insurers are emphasizing a few dental issues for plan sponsors to consider in 2020. Over-billing Though GE Canada isn’t focusing on dental benefits in this year’s renewal process, Diana McNiven, […]

Green Shield Canada launches benefits plan analytics tool

Green Shield Canada is launching a benefits plan analytics tool to help plan sponsors take a closer look at their offerings. The tool, DATAleap, looks to provide insight on claims trends, key cost drivers and disease state data. It also provides benchmarking tools for plans and demographics analyses. Read: Harnessing analytics, data to support employee mental health “Users can […]

  • By: Staff
  • March 16, 2020 November 12, 2020
  • 09:30

Historically, Epcor Utilities Inc. provided employees with $1,000 in annual coverage for each paramedical service, ranging from massage therapists, physiotherapists and chiropractors to speech therapists, naturopaths and dieticians. But in 2018, the Edmonton-based utilities company looked at its annual paramedical costs and found its massage therapy spend had ballooned to nearly match the cost of […]

A look at ROI benefits of employee mental-health programs

Workplace mental-health programs can demonstrate a huge return on investment for an organization’s bottom line, as well as reducing absenteeism and presenteeism, said Nir Yahav, mental-health specialist on the national disability best practices team at Manulife, during a session at Benefits Canada’s 2019 Vancouver Mental Health Summit on Dec. 12. There are huge costs associated with presenteeism, […]

Stigma, coverage barriers preventing proper treatment of migraine

While 2.7 million Canadians suffer from migraine, the condition can be subdivided based on its frequency, said Dr. Esma Dilli, neurologist and clinical assistant professor at the University of British Columbia, during Benefits Canada’s 2019 Vancouver Mental Health Summit on Dec. 12. Episodic migraine is defined by less than 15 headache days a month, whereas […]

What tools can employers use to address employees’ sleep concerns?

While insomnia is a disorder, it’s just as commonly a symptom, which most people and physicians don’t grasp, said Dr. Atul Khullar, medical director at the Northern Alberta Sleep Clinic. A lot of times, not sleeping is essentially the body breaking down because of a separate disorder, risk factor or residual symptom of a mental-health […]

Capping drug coverage for rare diseases poses an ethical dilemma

While high-cost specialty medications represent about 30 per cent of drug costs, the total budget impact of rare disease drugs is less than two per cent, said Brad McCaw, associate director of market access at Alexion Pharmaceuticals Canada. Within the high-cost specialty market’s top 20 drugs, only one is designated for rare disease, he said […]

Big pharma may cut R&D, delay new drugs if pharmacare means more generics: memo

Brand-name drug companies could put off introducing new medicine in Canada and scale back research here if the country makes a major shift to cheaper generic alternatives under a national pharmacare plan, according to an internal federal analysis. The concerns were included last year in a briefing document for federal Finance Minister Bill Morneau that […]

Budget 2019: Feds to develop a strategy for high-cost drugs for rare diseases

In its 2019 budget on Tuesday, the federal government confirmed it will work with partners to move forward on three foundational elements of national pharmacare. The initial steps are the creation of a new national drug agency and a national formulary, which were both recommended by the advisory council on the implementation of national pharmacare in its interim […]

2019 Drug Plan Trends Report: What’s next for drug plans?

Though many plan sponsors are still using step therapy to manage drug plan costs, pharmacogenetic testing is receiving attention as more providers enter the market, lower the cost and familiarize employers and insurers with the technology. As it becomes more sophisticated, there’s more information about how pharmacogentic testing works, says Sandra Ventin, associate vice-president at […]

  • By: Jann Lee
  • March 15, 2019 March 6, 2021
  • 08:53